Analyst Ratings For Flexion Therapeutics (NASDAQ:FLXN)
Today, Berenberg Bank initiated coverage on Flexion Therapeutics (NASDAQ:FLXN) with a Buy with a price target of $42.00.
Some recent analyst ratings include
- 2/1/2018-Berenberg Bank initiated coverage with a Buy rating.
- 11/10/2017-Northland Securities Reiterated Rating of Buy.
- 10/10/2017-Laidlaw Reiterated Rating of Buy.
- 10/9/2017-BMO Capital Markets Reiterated Rating of Outperform.
Recent Insider Trading Activity For Flexion Therapeutics (NASDAQ:FLXN)
Flexion Therapeutics (NASDAQ:FLXN) has insider ownership of 15.98% and institutional ownership of 72.78%.
- On 11/21/2017 Neil Bodick, Insider, bought 2,700 with an average share price of $24.49 per share and the total transaction amounting to $66,123.00.
- On 11/8/2017 Michael D Clayman, Insider, bought 5,000 with an average share price of $23.60 per share and the total transaction amounting to $118,000.00.
- On 9/5/2017 Yamo Deniz, Insider, bought 1,000 with an average share price of $24.20 per share and the total transaction amounting to $24,200.00.
- On 9/1/2017 Yamo Deniz, Insider, bought 3,000 with an average share price of $24.15 per share and the total transaction amounting to $72,450.00.
- On 8/31/2017 Yamo Deniz, Insider, bought 1,375 with an average share price of $25.40 per share and the total transaction amounting to $34,925.00.
- On 6/16/2017 Mark Stejbach, Director, bought 1,580 with an average share price of $17.02 per share and the total transaction amounting to $26,891.60.
- On 6/5/2017 Michael D Clayman, Insider, bought 5,000 with an average share price of $17.23 per share and the total transaction amounting to $86,150.00.
Recent Trading Activity for Flexion Therapeutics (NASDAQ:FLXN)
Shares of Flexion Therapeutics closed the previous trading session at 22.83 up +0.24 1.06% with 22.514999389648438 shares trading hands.